

Global Common Cancer-associated Antigens (CAAs) Vaccine Market Insights, Forecast to 2029

<https://marketpublishers.com/r/G1FD4AA033FCEN.html>

Date: December 2023

Pages: 98

Price: US\$ 4,900.00 (Single User License)

ID: G1FD4AA033FCEN

Abstracts

This report presents an overview of global market for Common Cancer-associated Antigens (CAAs) Vaccine market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Common Cancer-associated Antigens (CAAs) Vaccine, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Common Cancer-associated Antigens (CAAs) Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Common Cancer-associated Antigens (CAAs) Vaccine revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Common Cancer-associated Antigens (CAAs) Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Common Cancer-associated Antigens (CAAs) Vaccine revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Seattle Genetics, Merck Serono, Merck KGaA, GlaxoSmithKline, KAEL-GemVax, SELLAS Life Sciences, Celldex and Immatics Biotechnologies, etc.

By Company

Seattle Genetics

Merck Serono

Merck KGaA

GlaxoSmithKline

KAEL-GemVax

SELLAS Life Sciences

Celldex

Immatics Biotechnologies

Segment by Type

Tecemotide

Astuprotimut-R

Tertomotide

Nelipepimut-S

Others

Segment by Application

Pediatrics

Adults

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East, Africa, and Latin America

Turkey

Saudi Arabia

UAE

Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Common Cancer-associated Antigens (CAAs) Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant

policies in the industry.

Chapter 3: Detailed analysis of Common Cancer-associated Antigens (CAAs) Vaccine companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America by type, by application and by country, revenue for each segment.

Chapter 7: Europe by type, by application and by country, revenue for each segment.

Chapter 8: China by type and by application revenue for each segment.

Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Common Cancer-associated Antigens (CAAs) Vaccine revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Market Analysis by Type
 - 1.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
 - 1.2.2 Tecemotide
 - 1.2.3 Astuprotimut-R
 - 1.2.4 Tertomotide
 - 1.2.5 Nelipepimut-S
 - 1.2.6 Others
- 1.3 Market by Application
 - 1.3.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
 - 1.3.2 Pediatrics
 - 1.3.3 Adults
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered

2 GLOBAL GROWTH TRENDS

- 2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Perspective (2018-2029)
- 2.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Growth Trends by Region
 - 2.2.1 Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region: 2018 VS 2022 VS 2029
 - 2.2.2 Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Region (2018-2023)
 - 2.2.3 Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Region (2024-2029)
- 2.3 Common Cancer-associated Antigens (CAAs) Vaccine Market Dynamics
 - 2.3.1 Common Cancer-associated Antigens (CAAs) Vaccine Industry Trends
 - 2.3.2 Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers
 - 2.3.3 Common Cancer-associated Antigens (CAAs) Vaccine Market Challenges
 - 2.3.4 Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Revenue Common Cancer-associated Antigens (CAAs) Vaccine by Players

3.1.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue by Players (2018-2023)

3.1.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Players (2018-2023)

3.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Common Cancer-associated Antigens (CAAs) Vaccine, Ranking by Revenue, 2021 VS 2022 VS 2023

3.4 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Concentration Ratio

3.4.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Common Cancer-associated Antigens (CAAs) Vaccine Revenue in 2022

3.5 Global Key Players of Common Cancer-associated Antigens (CAAs) Vaccine Head office and Area Served

3.6 Global Key Players of Common Cancer-associated Antigens (CAAs) Vaccine, Product and Application

3.7 Global Key Players of Common Cancer-associated Antigens (CAAs) Vaccine, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 COMMON CANCER-ASSOCIATED ANTIGENS (CAAS) VACCINE BREAKDOWN DATA BY TYPE

4.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Type (2018-2023)

4.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Type (2024-2029)

5 COMMON CANCER-ASSOCIATED ANTIGENS (CAAS) VACCINE BREAKDOWN DATA BY APPLICATION

5.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Application (2018-2023)

5.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)

6.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type

6.2.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2018-2023)

6.2.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2024-2029)

6.2.3 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2018-2029)

6.3 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application

6.3.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2018-2023)

6.3.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2024-2029)

6.3.3 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2018-2029)

6.4 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country

6.4.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country: 2018 VS 2022 VS 2029

6.4.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023)

6.4.3 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029)

6.4.4 United States

6.4.5 Canada

7 EUROPE

7.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)

7.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type

7.2.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2018-2023)

7.2.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2024-2029)

7.2.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2018-2029)

7.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application

7.3.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2018-2023)

7.3.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2024-2029)

7.3.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2018-2029)

7.4 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country

7.4.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country: 2018 VS 2022 VS 2029

7.4.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023)

7.4.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 CHINA

8.1 China Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)

8.2 China Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type

8.2.1 China Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2018-2023)

8.2.2 China Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2024-2029)

8.2.3 China Common Cancer-associated Antigens (CAAs) Vaccine Market Share by

Type (2018-2029)

8.3 China Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application

8.3.1 China Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2018-2023)

8.3.2 China Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2024-2029)

8.3.3 China Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2018-2029)

9 ASIA (EXCLUDING CHINA)

9.1 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)

9.2 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type

9.2.1 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2018-2023)

9.2.2 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2024-2029)

9.2.3 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2018-2029)

9.3 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application

9.3.1 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2018-2023)

9.3.2 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2024-2029)

9.3.3 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2018-2029)

9.4 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region

9.4.1 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region: 2018 VS 2022 VS 2029

9.4.2 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2018-2023)

9.4.3 Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2024-2029)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 MIDDLE EAST, AFRICA, AND LATIN AMERICA

10.1 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2018-2029)

10.2 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type

10.2.1 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2018-2023)

10.2.2 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2024-2029)

10.2.3 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2018-2029)

10.3 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application

10.3.1 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2018-2023)

10.3.2 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2024-2029)

10.3.3 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2018-2029)

10.4 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country

10.4.1 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country: 2018 VS 2022 VS 2029

10.4.2 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023)

10.4.3 Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 KEY PLAYERS PROFILES

11.1 Seattle Genetics

11.1.1 Seattle Genetics Company Details

11.1.2 Seattle Genetics Business Overview

11.1.3 Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine

Introduction

11.1.4 Seattle Genetics Revenue in Common Cancer-associated Antigens (CAAs)

Vaccine Business (2018-2023)

11.1.5 Seattle Genetics Recent Developments

11.2 Merck Serono

11.2.1 Merck Serono Company Details

11.2.2 Merck Serono Business Overview

11.2.3 Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine

Introduction

11.2.4 Merck Serono Revenue in Common Cancer-associated Antigens (CAAs)

Vaccine Business (2018-2023)

11.2.5 Merck Serono Recent Developments

11.3 Merck KGaA

11.3.1 Merck KGaA Company Details

11.3.2 Merck KGaA Business Overview

11.3.3 Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine

Introduction

11.3.4 Merck KGaA Revenue in Common Cancer-associated Antigens (CAAs)

Vaccine Business (2018-2023)

11.3.5 Merck KGaA Recent Developments

11.4 GlaxoSmithKline

11.4.1 GlaxoSmithKline Company Details

11.4.2 GlaxoSmithKline Business Overview

11.4.3 GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine

Introduction

11.4.4 GlaxoSmithKline Revenue in Common Cancer-associated Antigens (CAAs)

Vaccine Business (2018-2023)

11.4.5 GlaxoSmithKline Recent Developments

11.5 KAEL-GemVax

11.5.1 KAEL-GemVax Company Details

11.5.2 KAEL-GemVax Business Overview

11.5.3 KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine

Introduction

11.5.4 KAEL-GemVax Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

11.5.5 KAEL-GemVax Recent Developments

11.6 SELLAS Life Sciences

11.6.1 SELLAS Life Sciences Company Details

11.6.2 SELLAS Life Sciences Business Overview

11.6.3 SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Introduction

11.6.4 SELLAS Life Sciences Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

11.6.5 SELLAS Life Sciences Recent Developments

11.7 Celldex

11.7.1 Celldex Company Details

11.7.2 Celldex Business Overview

11.7.3 Celldex Common Cancer-associated Antigens (CAAs) Vaccine Introduction

11.7.4 Celldex Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

11.7.5 Celldex Recent Developments

11.8 Immatics Biotechnologies

11.8.1 Immatics Biotechnologies Company Details

11.8.2 Immatics Biotechnologies Business Overview

11.8.3 Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Introduction

11.8.4 Immatics Biotechnologies Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

11.8.5 Immatics Biotechnologies Recent Developments

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Type (US\$ Million), 2018 VS 2022 VS 2029

Table 2. Key Players of Tecemotide

Table 3. Key Players of Astuprotimut-R

Table 4. Key Players of Tertomotide

Table 5. Key Players of Nelipepimut-S

Table 6. Key Players of Others

Table 7. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Application (US\$ Million), 2018 VS 2022 VS 2029

Table 8. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate (CAGR) by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 9. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2018-2023) & (US\$ Million)

Table 10. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region (2018-2023)

Table 11. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 12. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region (2024-2029)

Table 13. Common Cancer-associated Antigens (CAAs) Vaccine Market Trends

Table 14. Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers

Table 15. Common Cancer-associated Antigens (CAAs) Vaccine Market Challenges

Table 16. Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints

Table 17. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue by Players (2018-2023) & (US\$ Million)

Table 18. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Share by Players (2018-2023)

Table 19. Global Top Common Cancer-associated Antigens (CAAs) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Common Cancer-associated Antigens (CAAs) Vaccine as of 2022)

Table 20. Global Common Cancer-associated Antigens (CAAs) Vaccine Industry Ranking 2021 VS 2022 VS 2023

Table 21. Global 5 Largest Players Market Share by Common Cancer-associated Antigens (CAAs) Vaccine Revenue (CR5 and HHI) & (2018-2023)

Table 22. Global Key Players of Common Cancer-associated Antigens (CAAs) Vaccine,

Headquarters and Area Served

Table 23. Global Key Players of Common Cancer-associated Antigens (CAAs) Vaccine, Product and Application

Table 24. Global Key Players of Common Cancer-associated Antigens (CAAs) Vaccine, Product and Application

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2018-2023) & (US\$ Million)

Table 27. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Type (2018-2023)

Table 28. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 29. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Type (2024-2029)

Table 30. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2018-2023) & (US\$ Million)

Table 31. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Share by Application (2018-2023)

Table 32. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 33. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Share by Application (2024-2029)

Table 34. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2018-2023) & (US\$ Million)

Table 35. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2024-2029) & (US\$ Million)

Table 36. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2018-2023) & (US\$ Million)

Table 37. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2024-2029) & (US\$ Million)

Table 38. North America Common Cancer-associated Antigens (CAAs) Vaccine Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 39. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023) & (US\$ Million)

Table 40. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029) & (US\$ Million)

Table 41. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2018-2023) & (US\$ Million)

Table 42. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size

by Type (2024-2029) & (US\$ Million)

Table 43. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2018-2023) & (US\$ Million)

Table 44. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2024-2029) & (US\$ Million)

Table 45. Europe Common Cancer-associated Antigens (CAAs) Vaccine Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 46. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023) & (US\$ Million)

Table 47. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029) & (US\$ Million)

Table 48. China Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2018-2023) & (US\$ Million)

Table 49. China Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2024-2029) & (US\$ Million)

Table 50. China Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2018-2023) & (US\$ Million)

Table 51. China Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2024-2029) & (US\$ Million)

Table 52. Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2018-2023) & (US\$ Million)

Table 53. Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2024-2029) & (US\$ Million)

Table 54. Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2018-2023) & (US\$ Million)

Table 55. Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2024-2029) & (US\$ Million)

Table 56. Asia Common Cancer-associated Antigens (CAAs) Vaccine Growth Rate (CAGR) by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 57. Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2018-2023) & (US\$ Million)

Table 58. Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2024-2029) & (US\$ Million)

Table 59. Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2018-2023) & (US\$ Million)

Table 60. Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2024-2029) & (US\$ Million)

Table 61. Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2018-2023) & (US\$ Million)

- Table 62. Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2024-2029) & (US\$ Million)
- Table 63. Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029
- Table 64. Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2018-2023) & (US\$ Million)
- Table 65. Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2024-2029) & (US\$ Million)
- Table 66. Seattle Genetics Company Details
- Table 67. Seattle Genetics Business Overview
- Table 68. Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Product
- Table 69. Seattle Genetics Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)
- Table 70. Seattle Genetics Recent Developments
- Table 71. Merck Serono Company Details
- Table 72. Merck Serono Business Overview
- Table 73. Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Product
- Table 74. Merck Serono Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)
- Table 75. Merck Serono Recent Developments
- Table 76. Merck KGaA Company Details
- Table 77. Merck KGaA Business Overview
- Table 78. Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Product
- Table 79. Merck KGaA Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)
- Table 80. Merck KGaA Recent Developments
- Table 81. GlaxoSmithKline Company Details
- Table 82. GlaxoSmithKline Business Overview
- Table 83. GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Product
- Table 84. GlaxoSmithKline Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)
- Table 85. GlaxoSmithKline Recent Developments
- Table 86. KAEL-GemVax Company Details
- Table 87. KAEL-GemVax Business Overview
- Table 88. KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Product
- Table 89. KAEL-GemVax Revenue in Common Cancer-associated Antigens (CAAs)

Vaccine Business (2018-2023) & (US\$ Million)

Table 90. KANEL-GemVax Recent Developments

Table 91. SELLAS Life Sciences Company Details

Table 92. SELLAS Life Sciences Business Overview

Table 93. SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Product

Table 94. SELLAS Life Sciences Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)

Table 95. SELLAS Life Sciences Recent Developments

Table 96. Celldex Company Details

Table 97. Celldex Business Overview

Table 98. Celldex Common Cancer-associated Antigens (CAAs) Vaccine Product

Table 99. Celldex Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)

Table 100. Celldex Recent Developments

Table 101. Immatix Biotechnologies Company Details

Table 102. Immatix Biotechnologies Business Overview

Table 103. Immatix Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Product

Table 104. Immatix Biotechnologies Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023) & (US\$ Million)

Table 105. Immatix Biotechnologies Recent Developments

Table 106. Research Programs/Design for This Report

Table 107. Key Data Information from Secondary Sources

Table 108. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US\$ Million)

Figure 2. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type: 2022 VS 2029

Figure 3. Tecemotide Features

Figure 4. Astuprotimut-R Features

Figure 5. Tertomotide Features

Figure 6. Nelipepimut-S Features

Figure 7. Others Features

Figure 8. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US\$ Million)

Figure 9. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application: 2022 VS 2029

Figure 10. Pediatrics Case Studies

Figure 11. Adults Case Studies

Figure 12. Common Cancer-associated Antigens (CAAs) Vaccine Report Years Considered

Figure 13. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 14. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 15. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region: 2022 VS 2029

Figure 16. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Players in 2022

Figure 17. Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Common Cancer-associated Antigens (CAAs) Vaccine as of 2022)

Figure 18. The Top 10 and 5 Players Market Share by Common Cancer-associated Antigens (CAAs) Vaccine Revenue in 2022

Figure 19. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 20. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2018-2029)

Figure 21. North America Common Cancer-associated Antigens (CAAs) Vaccine Market

Share by Application (2018-2029)

Figure 22. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2018-2029)

Figure 23. United States Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Canada Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY (2018-2029) & (US\$ Million)

Figure 26. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2018-2029)

Figure 27. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2018-2029)

Figure 28. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2018-2029)

Figure 29. Germany Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. France Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. U.K. Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Italy Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Russia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. Nordic Countries Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. China Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY (2018-2029) & (US\$ Million)

Figure 36. China Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2018-2029)

Figure 37. China Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2018-2029)

Figure 38. Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY (2018-2029) & (US\$ Million)

Figure 39. Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2018-2029)

Figure 40. Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2018-2029)

Figure 41. Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region (2018-2029)

Figure 42. Japan Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. South Korea Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. China Taiwan Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Southeast Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. India Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Australia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 48. Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY (2018-2029) & (US\$ Million)

Figure 49. Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2018-2029)

Figure 50. Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2018-2029)

Figure 51. Middle East, Africa, and Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2018-2029)

Figure 52. Brazil Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 53. Mexico Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 54. Turkey Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 55. Saudi Arabia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 56. Israel Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 57. GCC Countries Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 58. Seattle Genetics Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

Figure 59. Merck Serono Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2018-2023)

Figure 60. Merck KGaA Revenue Growth Rate in Common Cancer-associated Antigens

(CAAs) Vaccine Business (2018-2023)

Figure 61. GlaxoSmithKline Revenue Growth Rate in Common Cancer-associated Antigen (CAAs) Vaccine Business (2018-2023)

Figure 62. Kaelin-GemVax Revenue Growth Rate in Common Cancer-associated Antigen (CAAs) Vaccine Business (2018-2023)

Figure 63. SELLAS Life Sciences Revenue Growth Rate in Common Cancer-associated Antigen (CAAs) Vaccine Business (2018-2023)

Figure 64. Celldex Revenue Growth Rate in Common Cancer-associated Antigen (CAAs) Vaccine Business (2018-2023)

Figure 65. Immatics Biotechnologies Revenue Growth Rate in Common Cancer-associated Antigen (CAAs) Vaccine Business (2018-2023)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

I would like to order

Product name: Global Common Cancer-associated Antigens (CAAs) Vaccine Market Insights, Forecast to 2029

Product link: <https://marketpublishers.com/r/G1FD4AA033FCEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1FD4AA033FCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

